Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:51 UTC |
Senner Christopher J.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000912282-26-000830 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2036-06-11 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:57 UTC |
Lamond DavidDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000912282-26-000832 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 2,700 shares Expires 2036-06-11 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 6,837,319 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 9 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,837,319 Underlying: Common Stock · 6,837,319 shares Expires 2036-05-11 F9 · kind: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F9 · price: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F10 · derivative.exercise_date: Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 6,837,319 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 8 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,837,319 Underlying: Common Stock · 6,837,319 shares Expires 2036-05-11 F9 · kind: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F9 · price: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,070,107 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 7 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070,107 Underlying: Common Stock · 2,070,107 shares Expires 2036-03-15 F8 · kind: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F8 · price: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 133,615 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 6 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,615 Underlying: Common Stock · 133,615 shares Expires 2034-08-12 F7 · kind: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F7 · price: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 362,092 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 5 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,092 Underlying: Common Stock · 362,092 shares Expires 2034-03-14 F6 · kind: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F6 · price: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 69,350 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 4 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,350 Underlying: Common Stock · 69,350 shares Expires 2033-07-30 F5 · kind: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F5 · price: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 124,830 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 3 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,830 Underlying: Common Stock · 124,830 shares Expires 2032-09-05 F4 · kind: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F4 · price: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 228,855 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 2 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,855 Underlying: Common Stock · 228,855 shares Expires 2032-04-07 F3 · kind: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F3 · price: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC |
Roberts BrigetteDirector · Chief Corp. Affairs Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 34,675 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 1 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,675 Underlying: Common Stock · 34,675 shares Expires 2031-03-01 F1 · kind: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. F1 · price: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 20:25 UTC |
Thye DirkDirector · CEO and CMO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000912282-26-000121 · form4.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2036-01-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 20:07 UTC |
Ryan Charles S.President
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000912282-26-000120 · form4.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2036-01-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. Read SEC document |
| January 23, 2026 Filed Jan 24, 2026 01:05 UTC |
Hannah BrendanCBO, COO & CCO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 365,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000912282-26-000119 · form4.xml · derivative · entry 1 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Shares · 365,000 shares Expires 2036-01-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 23:14 UTC |
Senner Christopher J.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 21,810 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000089 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,810 Underlying: Common Stock · 21,810 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 23:10 UTC |
McLoughlin MargaretDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 19,547 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000087 · form4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,547 Underlying: Common Stock · 19,547 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 22:59 UTC |
Bray JuneDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 18,724 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000083 · form4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,724 Underlying: Common Shares · 18,724 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 23:05 UTC |
Lamond DavidDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 29,423 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000085 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,423 Underlying: Common Stock · 29,423 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 17:36 UTC |
Benatti LucaDirector
|
SaleCommon Stock | 50,000 | $3.47 | $173,500.00 |
DisclosureSEC source: 0000912282-25-001469 · form4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,179 F1 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 17:07 UTC |
Thye DirkDirector · CEO and CMO
|
GiftCommon Shares | 739,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001407 · form4.xml · nonDerivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Indirect · Thye Trust Disclosed balance after: 739,885 Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 17:07 UTC |
Thye DirkDirector · CEO and CMO
|
GiftCommon Shares | 739,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001407 · form4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 13:12 UTC |
Hannah BrendanCBO, COO & CCO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,280 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0000912282-25-001370 · form4.xml · derivative · entry 4 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,720 Underlying: Common Shares · 25,280 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents grant of 225,000 employee stock options on February 2, 2023, which vest in equal monthly installments at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, with full vesting on the fourth annual anniversary of the vesting commencement date. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 13:12 UTC |
Hannah BrendanCBO, COO & CCO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,271 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000912282-25-001370 · form4.xml · derivative · entry 3 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,168 Underlying: Common Shares · 2,271 shares Expires 2032-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents grant of 103,500 employee stock options on May 19, 2022, which vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 13:12 UTC |
Hannah BrendanCBO, COO & CCO
|
Exercise / conversionCommon Shares | 25,280 | $0.94 | $23,763.20 |
DisclosureSEC source: 0000912282-25-001370 · form4.xml · nonDerivative · entry 2 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 13:12 UTC |
Hannah BrendanCBO, COO & CCO
|
Exercise / conversionCommon Shares | 2,271 | $0.55 | $1,249.05 |
DisclosureSEC source: 0000912282-25-001370 · form4.xml · nonDerivative · entry 1 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:43 UTC |
Thye DirkDirector · CEO and CMO
|
GrantWarrants · Derivative | 150,944 | $0.13 Strike: $1.20 | $18,868.00 |
DisclosureSEC source: 0000912282-25-000695 · form4.xml · derivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,944 Underlying: Common Shares · 150,944 shares Expires 2030-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:43 UTC |
Thye DirkDirector · CEO and CMO
|
GrantCommon Shares | 150,944 | $1.20 | $181,132.80 |
DisclosureSEC source: 0000912282-25-000695 · form4.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,885 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:46 UTC |
Ryan Charles S.President
|
GrantWarrants · Derivative | 7,548 | $0.13 Strike: $1.20 | $943.50 |
DisclosureSEC source: 0000912282-25-000696 · form4.xml · derivative · entry 2 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,548 Underlying: Common Shares · 7,548 shares Expires 2030-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 08:46 UTC |
Ryan Charles S.President
|
GrantCommon Shares | 7,548 | $1.20 | $9,057.60 |
DisclosureSEC source: 0000912282-25-000696 · form4.xml · nonDerivative · entry 1 Ryan Charles S. · CIK 0001624830 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,009 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 12:48 UTC |
Hannah BrendanCBO, COO & CCO
|
GrantWarrants · Derivative | 37,736 | $0.13 Strike: $1.20 | $4,717.00 |
DisclosureSEC source: 0000912282-25-000697 · form4.xml · derivative · entry 2 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,736 Underlying: Common Shares · 37,736 shares Expires 2030-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 12:48 UTC |
Hannah BrendanCBO, COO & CCO
|
GrantCommon Shares | 37,736 | $1.20 | $45,283.20 |
DisclosureSEC source: 0000912282-25-000697 · form4.xml · nonDerivative · entry 1 Hannah Brendan · CIK 0001929422 · CBO, COO & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,276 Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:52 UTC |
RYAN UNA SDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000625 · form4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:38 UTC |
Benatti LucaDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000623 · form4.xml · derivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:14 UTC |
Patni RajivDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000615 · form4.xml · derivative · entry 1 Patni Rajiv · CIK 0001616200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:36 UTC |
Senner Christopher J.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000621 · form4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:33 UTC |
Lamond DavidDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000619 · form4.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:27 UTC |
McLoughlin MargaretDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000617 · form4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:07 UTC |
Bray JuneDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000613 · form4.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| January 28, 2025 Filed Feb 11, 2025 17:44 UTC |
Thye DirkDirector · CEO AND CHIEF MEDICAL OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001415889-25-003618 · form4-02112025_100234.xml · derivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| January 28, 2025 Filed Feb 11, 2025 17:43 UTC |
Ryan Charles S.PRESIDENT
|
GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001415889-25-003615 · form4-02112025_100214.xml · derivative · entry 1 Ryan Charles S. · CIK 0001624830 · PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| January 28, 2025 Filed Feb 11, 2025 22:41 UTC |
Hannah BrendanCBO, COO and CCO
|
GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001415889-25-003613 · form4-02112025_100238.xml · derivative · entry 1 Hannah Brendan · CIK 0001929422 · CBO, COO and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:29 UTC |
Senner Christopher J.Director
|
GrantDirector Stock Option (right to buy) · Derivative | 35,274 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001160 · form4-01092025_120111.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,274 Underlying: Common Stock · 35,274 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:33 UTC |
McLoughlin MargaretDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 31,613 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001164 · form4-01092025_120123.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,613 Underlying: Common Stock · 31,613 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:32 UTC |
Bray JuneDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 30,282 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001163 · form4-01092025_120106.xml · derivative · entry 1 Bray June · CIK 0001845487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,282 Underlying: Common Stock · 30,282 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:30 UTC |
Lamond DavidDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 47,587 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001162 · form4-01092025_120154.xml · derivative · entry 1 Lamond David · CIK 0001770790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,587 Underlying: Common Stock · 47,587 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| October 23, 2024 Filed Dec 29, 2025 17:34 UTC |
Benatti LucaDirector
|
OtherCommon Stock | 8,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-25-001468 · form4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,179 F1 · kind: In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024. F1 · price: In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024. Read SEC document |
| August 30, 2024 Filed Sep 3, 2024 17:38 UTC |
Thye DirkDirector · CEO AND CHIEF MEDICAL OFFICER
|
PurchaseCommon Stock | 77,000 | $0.70 | $53,900.00 |
DisclosureSEC source: 0001415889-24-022702 · form4-09032024_090940.xml · nonDerivative · entry 2 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,941 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 17:38 UTC |
Thye DirkDirector · CEO AND CHIEF MEDICAL OFFICER
|
PurchaseCommon Stock | 77,500 | $0.69 | $53,475.00 |
DisclosureSEC source: 0001415889-24-022702 · form4-09032024_090940.xml · nonDerivative · entry 1 Thye Dirk · CIK 0001638945 · Director · CEO AND CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,941 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:38 UTC |
Hannah BrendanCHIEF BUSINESS OFFICER AND COO
|
PurchaseCommon Stock | 23,565 | $0.63 | $14,845.95 |
DisclosureSEC source: 0001415889-24-021869 · form4-08212024_100803.xml · nonDerivative · entry 6 Hannah Brendan · CIK 0001929422 · CHIEF BUSINESS OFFICER AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,540 Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:38 UTC |
Hannah BrendanCHIEF BUSINESS OFFICER AND COO
|
PurchaseCommon Stock | 5,000 | $0.62 | $3,100.00 |
DisclosureSEC source: 0001415889-24-021869 · form4-08212024_100803.xml · nonDerivative · entry 5 Hannah Brendan · CIK 0001929422 · CHIEF BUSINESS OFFICER AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,975 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.